Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...

Pfizer has outperformed the S&P 500 since my previous call, driven by improving fundamentals and renewed share price momentum ...

Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings ...

Shares of Pfizer Inc. PFE rallied 1.71% to $25.58 Wednesday, on what proved to be an all-around poor trading session for the ...

Dividend-paying stocks can really boost an individual investor's portfolio. If you're in the market for some no-brainer ...

Pfizer PFE stock has declined almost 5% in a month, losing $7.3 billion in market capitalization. Shares dipped recently ...

In the latest close session, Pfizer (PFE) was up +1.63% at $25.56. This move outpaced the S&P 500's daily loss of 0.53%. On ...

In the latest close session, Pfizer (PFE) was up +1.12% at $25.18. The stock outpaced the S&P 500's daily gain of 0.19%. Meanwhile, the Dow experienced a rise of 0.66%, and the technology-dominated ...

However, there's one potentially lucrative growth opportunity that Pfizer's focusing on that could change things and ...

US stocks extended losses on Wednesday as weakness in tech megacaps outweighed solid economic data and mixed results from ...

While I believe Pfizer will rebound eventually, it will take some time to do so, and it may not occur in 2026. In the ...